Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T16:26:13.911Z.
Calculation as of: 2026-10-06T16:26:13.911Z.
Quote observation: 2026-10-06T16:25:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 979ff17a100a324a490b4ea8bab969f4c23ca35a684dd985742eca9c7cd70937
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2024-09-23.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
EV/FCF RATIO AVG TTM
N/A
EV/FCF RATIO AVG 3Y
N/A
EV/FCF RATIO AVG 5Y
N/A
EV/FCF RATIO AVG 10Y
N/A
EV/FCF RATIO AVG 15Y
N/A
EV/FCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$605.11M
EV/FCF Ratio
1085.12x
TTM Avg
684.49x
3Y Avg
684.49x
5Y Avg
386.65x
Market Cap
$599.19M
EV/FCF Ratio
4.94x
TTM Avg
12.45x
3Y Avg
11.11x
5Y Avg
9.59x
Market Cap
$669.77M
EV/FCF Ratio
13.20x
TTM Avg
10.66x
3Y Avg
30.61x
5Y Avg
30.61x
Market Cap
$670.70M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Climb Bio, Inc. (CLYM) | $632.18M | N/A | N/A | N/A | N/A |
| Prime Medicine, Inc. (PRME)vs › | $633.99M | N/A | N/A | N/A | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $635.27M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $657.45M | N/A | 710.97x | 756.83x | 756.83x |
| AngioDynamics, Inc. (ANGO)vs › | $605.11M | 1085.12x | 684.49x | 684.49x | 386.65x |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $599.19M | 4.94x | 12.45x | 11.11x | 9.59x |
| MiMedx Group, Inc. (MDXG)vs › | $669.77M | 13.20x | 10.66x | 30.61x | 30.61x |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $670.70M | N/A | N/A | N/A | N/A |
| OrthoPediatrics Corp. (KIDS)vs › | $589.15M | N/A | N/A | N/A | N/A |
| Fulgent Genetics, Inc. (FLGT)vs › | $588.32M | N/A | 53.49x | 23.98x | 29.09x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/FCF RATIO |
|---|---|
| 2024-09-23 | 149.60x |
| 2024-09-20 | 575.56x |
| 2024-09-19 | 495.69x |
| 2024-09-18 | 335.96x |
| 2024-09-17 | 325.31x |
| 2024-09-16 | 474.39x |
| 2024-09-13 | 591.53x |
| 2024-09-12 | 346.61x |
| 2024-09-11 | 277.39x |
| 2024-09-10 | 250.76x |
| 2024-09-09 | 256.09x |
